Immunic, Inc. (IMUX)

Immunic Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	16.87	16.01	15.26	30.55	10.33	14.52
Research & Development	78.99	83.22	71.26	61.12	38.64	22.51
Other Operating Expenses	0	0	32.97	0	0	0
Operating Expenses	95.85	99.22	119.49	91.67	48.97	37.03
Operating Income	-95.85	-99.22	-119.49	-91.67	-48.97	-37.03
Other Expense / Income	2.07	-5.61	0.92	1.28	-4.95	-2.1
Pretax Income	-97.92	-93.61	-120.41	-92.95	-44.02	-34.93
Net Income	-97.92	-93.61	-120.41	-92.95	-44.02	-34.93
Shares Outstanding (Basic)	97	44	32	24	16	8
Shares Outstanding (Diluted)	97	44	32	24	16	8
Shares Change	122.83%	39.29%	34.53%	51.00%	102.84%	811.77%
EPS (Basic)	-1.83	-2.11	-3.78	-3.93	-2.81	-4.52
EPS (Diluted)	-1.83	-2.11	-3.78	-3.93	-2.81	-4.52
Free Cash Flow	-75.55	-71.16	-65.26	-83.3	-46.27	-28.56
Free Cash Flow Per Share	-0.78	-1.61	-2.05	-3.52	-2.95	-3.70
EBITDA	-97.82	-93.5	-120.33	-92.86	-43.98	-34.88
Depreciation & Amortization	0.11	0.11	0.08	0.09	0.04	0.05
EBIT	-97.92	-93.61	-120.41	-92.95	-44.02	-34.93

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).